LINEAGE CELL THERAPEUTICS IN (LCTX)
US53566P1093 - Common Stock
ChartMill assigns a Buy % Consensus number of 82% to LCTX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 4.81. This target is 698.5% above the current price.
LCTX was analyzed by 13 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about LCTX.
In the previous month the buy percentage consensus was at a similar level.
LCTX was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-20 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-18 | D. Boral Capital | Initiate | Buy |
| 2024-08-20 | Craig-Hallum | Initiate | Buy |
| 2024-05-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-05 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-25 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-07-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-04-26 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-10 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-02 | Baird | Initiate | Outperform |
| 2022-06-14 | B. Riley Securities | Initiate | Buy |
| 2021-08-19 | Noble Capital Markets | Initiate | Outperform |
| 2021-03-31 | Cantor Fitzgerald | Initiate | Overweight |